Literature DB >> 20138813

Analysis of lidocaine interactions with serum proteins using high-performance affinity chromatography.

Sony Soman1, Michelle J Yoo, Yoon Jeong Jang, David S Hage.   

Abstract

High-performance affinity chromatography was used to study binding by the drug lidocaine to human serum albumin (HSA) and alpha(1)-acid glycoprotein (AGP). AGP had strong binding to lidocaine, with an association equilibrium constant (K(a)) of 1.1-1.7 x 10(5) M(-1) at 37 degrees C and pH 7.4. Lidocaine had weak to moderate binding to HSA, with a K(a) in the range of 10(3) to 10(4) M(-1). Competitive experiments with site selective probes showed that lidocaine was interacting with Sudlow site II of HSA and the propranolol site of AGP. These results agree with previous observations in the literature and provide a better quantitative understanding of how lidocaine binds to these serum proteins and is transported in the circulation. This study also demonstrates how HPAC can be used to examine the binding of a drug with multiple serum proteins and provide detailed information on the interaction sites and equilibrium constants that are involved in such processes. Copyright 2010. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20138813      PMCID: PMC2837466          DOI: 10.1016/j.jchromb.2010.01.016

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  21 in total

Review 1.  High-performance affinity chromatography and immobilized serum albumin as probes for drug- and hormone-protein binding.

Authors:  D S Hage; J Austin
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2000-02-28

2.  Medium-throughput pKa screening pharmaceuticals by pressure-assisted capillary electrophoresis.

Authors:  Z Jia; T Ramstad; M Zhong
Journal:  Electrophoresis       Date:  2001-04       Impact factor: 3.535

3.  Immobilization of alpha(1)-acid glycoprotein for chromatographic studies of drug-protein binding.

Authors:  Hai Xuan; David S Hage
Journal:  Anal Biochem       Date:  2005-09-19       Impact factor: 3.365

4.  In silico ADME modelling 2: computational models to predict human serum albumin binding affinity using ant colony systems.

Authors:  Sitarama B Gunturi; Ramamurthi Narayanan; Akash Khandelwal
Journal:  Bioorg Med Chem       Date:  2006-02-28       Impact factor: 3.641

5.  Chromatographic analysis of carbamazepine binding to human serum albumin. II. Comparison of the Schiff base and N-hydroxysuccinimide immobilization methods.

Authors:  Hee Seung Kim; Rangan Mallik; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-05-09       Impact factor: 3.205

6.  Evaluation of a hydrazide-linked alpha1-acid glycoprotein chiral stationary phase: separation of R- and S-propranolol.

Authors:  Hai Xuan; David S Hage
Journal:  J Sep Sci       Date:  2006-07       Impact factor: 3.645

7.  Stability of lidocaine in aqueous solution: effect of temperature, pH, buffer, and metal ions on amide hydrolysis.

Authors:  M F Powell
Journal:  Pharm Res       Date:  1987-02       Impact factor: 4.200

8.  Crystal structure of human serum albumin at 2.5 A resolution.

Authors:  S Sugio; A Kashima; S Mochizuki; M Noda; K Kobayashi
Journal:  Protein Eng       Date:  1999-06

9.  Characterization of minor site probes for human serum albumin by high-performance affinity chromatography.

Authors:  A Sengupta; D S Hage
Journal:  Anal Chem       Date:  1999-09-01       Impact factor: 6.986

10.  Determination of protein-drug binding constants by pressure-assisted capillary electrophoresis (PACE)/frontal analysis (FA).

Authors:  Zhongjiang Jia; Tore Ramstad; Min Zhong
Journal:  J Pharm Biomed Anal       Date:  2002-10-15       Impact factor: 3.935

View more
  8 in total

1.  Calculation of normalized drug concentrations in the presence of altered plasma protein binding.

Authors:  Florin Marcel Musteata
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

Review 2.  Pharmaceutical and biomedical applications of affinity chromatography: recent trends and developments.

Authors:  David S Hage; Jeanethe A Anguizola; Cong Bi; Rong Li; Ryan Matsuda; Efthimia Papastavros; Erika Pfaunmiller; John Vargas; Xiwei Zheng
Journal:  J Pharm Biomed Anal       Date:  2012-01-14       Impact factor: 3.935

Review 3.  High performance affinity chromatography and related separation methods for the analysis of biological and pharmaceutical agents.

Authors:  Chenhua Zhang; Elliott Rodriguez; Cong Bi; Xiwei Zheng; Doddavenkatana Suresh; Kyungah Suh; Zhao Li; Fawzi Elsebaei; David S Hage
Journal:  Analyst       Date:  2018-01-15       Impact factor: 4.616

4.  Characterization of solution-phase drug-protein interactions by ultrafast affinity extraction.

Authors:  Sandya R Beeram; Xiwei Zheng; Kyungah Suh; David S Hage
Journal:  Methods       Date:  2018-03-03       Impact factor: 3.608

5.  High-throughput analysis of drug dissociation from serum proteins using affinity silica monoliths.

Authors:  Michelle J Yoo; David S Hage
Journal:  J Sep Sci       Date:  2011-06-10       Impact factor: 3.645

6.  Chromatographic studies of drug interactions with alpha1-acid glycoprotein by ultrafast affinity extraction and peak profiling.

Authors:  Sandya Beeram; Cong Bi; Xiwei Zheng; David S Hage
Journal:  J Chromatogr A       Date:  2017-03-23       Impact factor: 4.759

7.  Entrapment of alpha1-acid glycoprotein in high-performance affinity columns for drug-protein binding studies.

Authors:  Cong Bi; Abby Jackson; John Vargas-Badilla; Rong Li; Giana Rada; Jeanethe Anguizola; Erika Pfaunmiller; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2015-11-27       Impact factor: 3.205

8.  Analysis of free drug fractions in serum by ultrafast affinity extraction and two-dimensional affinity chromatography using α1-acid glycoprotein microcolumns.

Authors:  Cong Bi; Xiwei Zheng; David S Hage
Journal:  J Chromatogr A       Date:  2016-01-04       Impact factor: 4.759

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.